Projects per year
Personal profile
Research Strategic Pillar
Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Brain Health
- Life Span Health
- Infectious/ Immunological Health
- Specialized Health
- Metabolic Health
Fingerprint
Dive into the research topics where Richard Rupp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Phase III, randomized, single-blind, placebo-controlled, multi-center study to evaluate non-interference of concomitant administration of routine pediatric vaccines on the antibody response of an investigational live-attenuated respiratory syncytial viru
Rupp, R. (PI)
5/8/24 → 5/7/29
Project: Research project
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of V181 Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults 59 Years of Age or Older
Rupp, R. (PI)
Merck Sharp and Cohme Corporation
10/17/23 → 10/16/28
Project: Research project
-
DMID Program Planning Agreement - Next Generation Covid-19 Vaccine Development Program
Rupp, R. (PI)
Leidos Biomedical Research, Inc.
8/18/23 → 12/31/25
Project: Research project
-
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V117 Formulation C in Healthy Adults
Rupp, R. (PI)
Merck Sharp and Cohme Corporation
6/28/23 → 6/27/28
Project: Research project
-
Disseminated vaccine-induced varicella infection in a kidney transplant recipient
Berman, M. A. & Rupp, R. E., Nov 2023, In: American Journal of Transplantation. 23, 11, p. 1806-1810 5 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study
Banniettis, N., Horn, M., Sadarangani, M., Patel, S. M., Greenberg, D., Oberdorfer, P., Klein, N. P., Rupp, R., Dagan, R., Richmond, P., Lumley, J., Zhou, W., Shi, Y., Tamms, G., Feemster, K., Lupinacci, R., Musey, L. & Bickham, K., Jul 1 2023, In: Pediatrics. 152, 1, e2022060428.Research output: Contribution to journal › Article › peer-review
-
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)
for the V114-029 PNEU-PED study group, Jan 27 2023, In: Vaccine. 41, 5, p. 1142-1152 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
The rapid progress in COVID vaccine development and implementation
Barrett, A. D. T., Titball, R. W., MacAry, P. A., Rupp, R. E., von Messling, V., Walker, D. H. & Fanget, N. V. J., Dec 2022, In: npj Vaccines. 7, 1, 20.Research output: Contribution to journal › Editorial › peer-review
Open Access -
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
for the Coronavirus Efficacy (COVE) Study Group, Nov 15 2022, In: Journal of Infectious Diseases. 226, 10, p. 1731-1742 12 p.Research output: Contribution to journal › Article › peer-review
Open Access